Current challenges of unresectable stage III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial?
Por:
Remon J., Levy A., Singh P., Hendriks L.E.L., Aldea M., Arrieta O.
Publicada:
1 ene 2022
Categoría:
Oncology
Resumen:
Consolidation anti-programmed death-ligand 1 has become a new standard of care in unresectable stage III non-small cell lung cancer (NSCLC) following chemo-radiotherapy (CTRT), based on the results of two phase III trials. Advances remain however needed, in particular to reduce the risk of distant relapse and for treatment personalization. Newer strategies are currently being tested, including consolidation with dual immune checkpoint inhibitors (ICIs), concurrent chemo-radioimmunotherapy and (chemo)-immunotherapy induction before CTRT. One randomized phase II reported better outcomes with a double ICI consolidation as compared with durvalumab alone. Three nonrandomized phase II trials also suggested that concurrent ICI-CTRT was feasible. Within this review, we summarize the current evidence, highlight ongoing trials and discuss challenges that will ideally lead to a cure for more patients with unresectable stage III NSCLC. © The Author(s), 2022.
Filiaciones:
Department of Medical Oncology, Centro Integral Oncológico Clara Campal (HM-CIOCC), Hospital HM Nou Delfos, HM Hospitales, Avinguda de Vallcarca, 151, Barcelona, 08023, Spain
Department of Radiation Oncology, International Center for Thoracic Cancers (CICT), Université Paris-Saclay, Gustave Roussy, Gustave Roussy, Villejuif, France
Department of Pulmonary and Critical Care Medicine, Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Haryana, Rohtak, India
Department of Pulmonary Diseases, GROW–School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, Netherlands
Department of Medical Oncology, International Center for Thoracic Cancers, Université Paris-Saclay, Gustave Roussy, Gustave Roussy, Villejuif, France
Thoracic Oncology Unit and Laboratory of Personalized Medicine, Instituto Nacional de Cancerología, Mexico City, Mexico
All Open Access, Gold
|